Announces Appointment of Artem Evdokimov, PhD as CEO
Buffalo, New York, May 4, 2016 – For immediate release HarkerBIO is pleased to announce the appointment of Artem Evdokimov, PhD to Chief Executive Officer. As an expert in the field of structural biology and small molecule therapeutics, and with nearly 20 years of leadership in the biotech and pharmaceutical industries, Dr. Evdokimov has the ideal scientific and managerial capabilities to support HarkerBIO’s rapid growth.
Dr. Evdokimov was recruited by the corporation 1 year ago to serve as Chief Scientific Officer, yet within a short time became deeply involved in client relations, sales, capital funding, strategic planning, and fiscal management.
In announcing the appointment, James Biltekoff, Executive Chairman of HarkerBIO, stated, “We are fortunate to have a gifted leader in Artem. He has demonstrated a rare combination of managerial, interpersonal, and scientific skills which make him well suited to lead HarkerBIO during rapid growth and further expansion. We are pleased to continue to build HarkerBIO as the leader in providing ‘gene-to-structure’ contract research organization services.”
“The Institute is fortunate to have Artem as CEO of the HarkerBIO group,” added Edward Snell, CEO of the Hauptman-Woodward Medical Research Institute which spun off HarkerBIO in 2014. “HarkerBIO has quickly made its mark as a leader supporting early stage structure based drug discovery initiatives within pharmaceutical and biotechnology companies and Artem has the ideal background to ensure continued success.”
HarkerBIO is currently considering proposals for an additional $1.5-2.0 million in expansion capital.
About HarkerBIO
HarkerBIO is the leading contract research organization (CRO) providing high-quality solutions for early stage drug development. Its core expertise lies in the production of pharmaceutically relevant proteins for biophysical screening and protein crystallography. HarkerBIO clients benefit from the company’s proficiencies in protein biochemistry, biophysical characterization, complete gene-to-structure studies, production of difficult to get proteins and protein complexes, rapid solution of new protein structures, iterative fragment and compound screening, and biophysical validation.
HarkerBIO’s investment in experienced people, leading-edge technology, and state-of-the-art laboratory facilities enables them to provide quality capabilities for gene-to-structure research. For more information www.harkerbio.com.
About Hauptman-Woodward Medical Research Institute
Founded in Buffalo, New York in 1956, the Hauptman-Woodward Medical Research Institute (HWI) is an internationally renowned, independent, non-profit facility specializing in the area of fundamental biomedical research known as structural biology. HWI’s work improves human health by studying the causes of diseases, as well as potential therapies, at their basic molecular level. HWI is a founding member of the Buffalo Niagara Medical Campus, and resides in a state-of-the-art research facility at 700 Ellicott Street. For more information, visit HWI’s website at http://www.hwi.buffalo.edu.
Buffalo, New York, May 4, 2016 – For immediate release HarkerBIO is pleased to announce the appointment of Artem Evdokimov, PhD to Chief Executive Officer. As an expert in the field of structural biology and small molecule therapeutics, and with nearly 20 years of leadership in the biotech and pharmaceutical industries, Dr. Evdokimov has the ideal scientific and managerial capabilities to support HarkerBIO’s rapid growth.
Dr. Evdokimov was recruited by the corporation 1 year ago to serve as Chief Scientific Officer, yet within a short time became deeply involved in client relations, sales, capital funding, strategic planning, and fiscal management.
In announcing the appointment, James Biltekoff, Executive Chairman of HarkerBIO, stated, “We are fortunate to have a gifted leader in Artem. He has demonstrated a rare combination of managerial, interpersonal, and scientific skills which make him well suited to lead HarkerBIO during rapid growth and further expansion. We are pleased to continue to build HarkerBIO as the leader in providing ‘gene-to-structure’ contract research organization services.”
“The Institute is fortunate to have Artem as CEO of the HarkerBIO group,” added Edward Snell, CEO of the Hauptman-Woodward Medical Research Institute which spun off HarkerBIO in 2014. “HarkerBIO has quickly made its mark as a leader supporting early stage structure based drug discovery initiatives within pharmaceutical and biotechnology companies and Artem has the ideal background to ensure continued success.”
HarkerBIO is currently considering proposals for an additional $1.5-2.0 million in expansion capital.
About HarkerBIO
HarkerBIO is the leading contract research organization (CRO) providing high-quality solutions for early stage drug development. Its core expertise lies in the production of pharmaceutically relevant proteins for biophysical screening and protein crystallography. HarkerBIO clients benefit from the company’s proficiencies in protein biochemistry, biophysical characterization, complete gene-to-structure studies, production of difficult to get proteins and protein complexes, rapid solution of new protein structures, iterative fragment and compound screening, and biophysical validation.
HarkerBIO’s investment in experienced people, leading-edge technology, and state-of-the-art laboratory facilities enables them to provide quality capabilities for gene-to-structure research. For more information www.harkerbio.com.
About Hauptman-Woodward Medical Research Institute
Founded in Buffalo, New York in 1956, the Hauptman-Woodward Medical Research Institute (HWI) is an internationally renowned, independent, non-profit facility specializing in the area of fundamental biomedical research known as structural biology. HWI’s work improves human health by studying the causes of diseases, as well as potential therapies, at their basic molecular level. HWI is a founding member of the Buffalo Niagara Medical Campus, and resides in a state-of-the-art research facility at 700 Ellicott Street. For more information, visit HWI’s website at http://www.hwi.buffalo.edu.
